Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05164653 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)

StatusActive, Not Recruiting
PhasePhase 4
Started2021-12-27
View on ClinicalTrials.gov ↗
The aim of this study is to assess the treatment effect of sacubitril valsartan versus conventional therapy for heart failure (HF) in admitted patients due to exacerbation of HF on the N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) concentrations.

Amendment record

Amended 6 times since 2021-12-20; most recent filed 2024-08-19. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-29.

2024-08-19
Amendment Study Status, Sponsor/Collaborators v6
2024-08-15
Amendment Study Status v5
2023-06-07
Amendment Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v4
2023-04-03
Amendment Study Identification, Study Status, Sponsor/Collaborators, Contacts/Locations v3
2023-01-24
Amendment Study Status v2
2021-12-27
Amendment Study Status v1
2021-12-20
Original filing
Trial Details
NCT Number NCT05164653
Lead Sponsor Saga University
Conditions Heart Failure
Enrollment 400 participants
Start Date 2021-12-27
Primary Completion 2024-02-08 (estimated)
Study Completion 2025-03 (estimated)
Updated on ClinicalTrials.gov 2024-08-21